A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.
- 18 Dec 2018 Results published in the Cancer
- 01 Oct 2018 Planned End Date changed from 31 Aug 2018 to 21 Oct 2018.